LONDON BROKER RATINGS: Morgan Stanley cuts Mondi; BofA cuts Ashtead
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More
| Price | 501.00p on 02-02-2026 at 19:30:05 |
|---|---|
| Change | 2.50p 0.5% |
| Buy | 499.50p |
| Sell | 498.00p |
| Last Trade: | Buy 4,229.00 at 501.00p |
| Day's Volume: | 699,832 |
| Last Close: | 501.00p |
| Open: | 494.50p |
| ISIN: | GB00B45C9X44 |
| Day's Range | 490.00p - 502.00p |
| 52wk Range: | 297.50p - 614.00p |
| Market Capitalisation: | £1.35b |
| VWAP: | 499.06183p |
| Shares in Issue: | 268.97m |
Chemring (CHG) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 4,229 | 501.00p | SI Trade Negotiated Trade |
17:06:05 - 02-Feb-26 |
| Sell* | 5,005 | 501.00p | SI Trade |
16:35:15 - 02-Feb-26 |
| Sell* | 408 | 501.00p | SI Trade |
16:35:15 - 02-Feb-26 |
| Sell* | 230,542 | 501.00p | Uncrossing Trade |
16:35:15 - 02-Feb-26 |
| Buy* | 50,000 | 499.50p | Suspected BUY Trade |
16:32:18 - 02-Feb-26 |
| Sell* | 408 | 499.00p | Automatic Execution |
16:29:59 - 02-Feb-26 |
| Sell* | 73 | 499.00p | Automatic Execution |
16:29:59 - 02-Feb-26 |
| Sell* | 116 | 499.00p | Automatic Execution |
16:29:59 - 02-Feb-26 |
| Buy* | 280 | 499.50p | Automatic Execution |
16:29:42 - 02-Feb-26 |
| Buy* | 600 | 499.50p | Automatic Execution |
16:29:42 - 02-Feb-26 |
Chemring (CHG) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 2nd Feb 2026 7:00 am | RNS | Total Voting Rights |
| 23rd Jan 2026 4:41 pm | RNS | Director/PDMR Shareholding |
| 12th Jan 2026 1:35 pm | RNS | Notice of AGM |
| 2nd Jan 2026 10:29 am | RNS | Total Voting Rights |
| 19th Dec 2025 11:53 am | RNS | Holding(s) in Company |
| 19th Dec 2025 11:53 am | RNS | Holding(s) in Company |
| 18th Dec 2025 7:00 am | RNS | Block listing Interim Review |
| 16th Dec 2025 7:00 am | RNS | Director/PDMR Shareholding |
| 16th Dec 2025 7:00 am | RNS | Director/PDMR Shareholding |
| 16th Dec 2025 7:00 am | RNS | Director/PDMR Shareholding |